REVOLUTION Medicines Revenue and Competitors
Estimated Revenue & Valuation
- REVOLUTION Medicines's estimated annual revenue is currently $100M per year.
- REVOLUTION Medicines received $56.0M in venture funding in April 2018.
- REVOLUTION Medicines's estimated revenue per employee is $171,296
- REVOLUTION Medicines's total funding is $486.9M.
Employee Data
- REVOLUTION Medicines has 584 Employees.
- REVOLUTION Medicines grew their employee count by 40% last year.
REVOLUTION Medicines's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | Executive Assistant to the CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CIO | Reveal Email/Phone |
5 | VP | Reveal Email/Phone |
6 | Chief Human Resources Officer | Reveal Email/Phone |
7 | Chief Information Officer | Reveal Email/Phone |
8 | Assistant to the Chief Medical Officer and EVP Clinical Development | Reveal Email/Phone |
9 | SVP, Head Global Patient Safety | Reveal Email/Phone |
10 | SVP, Medicinal Chemistry | Reveal Email/Phone |
REVOLUTION Medicines Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is REVOLUTION Medicines?
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$486.9M
Total Funding
584
Number of Employees
$100M
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
REVOLUTION Medicines News
Revolution Medicines (NASDAQ:RVMD) Rating Increased to Hold at Zacks Investment Research. Posted by admin on Apr 16th, 2022.
Revolution Medicines : RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound...
Wall Street is positive on Revolution Medicines Inc (RVMD). On average, analysts give RVMD a Strong Buy rating. The average price target is...
... highlighting challenges and opportunities of health care revolution ... its global leadership position at the forefront of medicines research and ...
In June, Frontier Medicines launched with a $67 million Series A ... And in July, Revolution Medicines raised a $100 million equity round for its ...
Other Companies in Redwood City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $101.9M | 617 | 0% | $767.5M |
#2 | $113.3M | 625 | N/A | N/A |
#3 | $120.3M | 627 | 17% | $927M |
#4 | $15M | 637 | -18% | N/A |
#5 | $121.4M | 659 | -20% | $119.5M |
REVOLUTION Medicines Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-02-05 | $45.0M | A | Third Rock Ventures, LLC | Article |
| 2016-12-21 | $25.0M | A | The Column Group | Article |
| 2018-04-25 | $56.0M | B | Nextech Invest | Article |